Maven Securities’s Altimmune ALT Stock Holding History

Maven Securities’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,408	Closed	-$48K	–	1034
2021 Q1	$48K	Buy	+3,408	New	+$55.1K	﹤0.01%	1092
2020 Q4	–	Sell	-25,000	Closed	-$325K	–	558
2020 Q3	$325K	Buy	+25,000	New	+$500K	0.03%	468

Other funds holding ALT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Maven Securities's ALT Position: Q2 2021 in Review

Maven Securities sold out of Altimmune (ALT) in Q2 2021, closing a stake of 3,408 shares — an estimated $48K sold.

Maven Securities first reported a position in ALT in Q3 2020 and held it in 2 quarters. The position peaked at $325K in Q3 2020. 109 funds tracked by Wall St. Rank hold ALT as of Q2 2021.

Maven Securities reported no remaining Altimmune position as of Q2 2021 after selling out during the quarter.
Maven Securities sold 3,408 Altimmune shares in Q2 2021, an estimated $48K.
Maven Securities first reported a position in Altimmune in Q3 2020 and held it in 2 quarters.
Maven Securities's Altimmune position peaked at $325K in Q3 2020.
109 funds tracked by Wall St. Rank held Altimmune as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.